https://www.selleckchem.com/pr....oducts/abtl-0812.htm
025). Hypoglycaemic events occurred in all patients (100%) before using insulin glargine U300, while the incidence of hypoglycaemic events gradually decreased to 74.3%, 68.6%, and 68.6% between months 1-3, 3-6, and 6-9, respectively. Of the 26 patients who declared their level of satisfaction, 23 (88.5%) were satisfied, 2 (7.7%) indicated that there was no significant difference, and 1 (3.8%) patient was unsatisfied. Over 9-16 months of follow-up, insulin glargine U300 led to a significant reduction not only of HbA levels but also of
Like
Comment
Share
